Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
Articles » Active Bacterial Core Surveillance: DBMD
 

Active Bacterial Core Surveillance: DBMD

Article title: Active Bacterial Core Surveillance: DBMD

Conditions: Group A streptococcus, Group B streptococcus, Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae

Source: DBMD



Active Bacterial Core Surveillance (ABCs)

  See ABCs Homepage
 
Purpose To determine the incidence and epidemiologic characteristics of invasive bacterial disease, determine molecular epidemiologic patterns and microbiologic characteristics for isolates causing disease, and to provide an infrastructure for nested special studies to identify risk factors and to evaluate prevention policies.
Pathogens Group A streptococcus, Group B streptococcus, Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae.
Population Approximately 34.2 million, some or all counties in the following states: California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee.
Case Definition Isolation of one of the five bacterial pathogens from a normally sterile site in a resident of the surveillance population.
Methodology Active laboratory-based surveillance of invasive disease in area residents. Collection of demographic, clinical data, and bacterial isolates. Regular laboratory audits to assess completeness of active surveillance and detect additional cases. Collaboration between state health departments, academic investigators, and CDC.
Disease Burden
  • Group A streptococcus -- 3.2 cases per 100,000; estimated 9,000 cases and 1,000 deaths annually in the United States
  • Group B streptococcus -- 6.9 cases per 100,000; estimated 18,900 cases and 1,900 deaths annually in the United States
  • Haemophilus influenzae -- 1.3 cases per 100,000; estimated 3,400 cases and 625 deaths annually in the United States
  • Neisseria meningitidis -- 0.8 cases per 100,000; estimated 2,200 cases and 275 deaths annually in the United States
  • Streptococcus pneumoniae -- 21.9 cases per 100,000; estimated 60,000 cases and 6,700 deaths annually in the United States
Challenges Increasing antimicrobial resistance; aging population.
Opportunities Measuring impact of newly licensed pneumococcal conjugate vaccine on disease and drug resistance; harnessing molecular techniques to characterize bacterial isolates.

December 2001

 
 
 

homepage | back to top
 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise